Comments: Antiviral product sales increased to $6.0 billion in the quarter driven by sales of Sovaldi, which launched in December 2013. Complera/Eviplera sales were $299.5 million, up 59%, and Stribild sales were $269.5 million, up 171%. Atripla sales declined 7% to $870.7 million and Truvada sales were flat in the quarter. Cardiovascular product sales increased to $266.7 million, up 14% with Letairis sales of $144.7 million, and Ranexa sales of $122.0 million.